Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice

Michael Offin*1*, Valerie W. Rusch2, Andreas Rimner3*, Prasad S. Adusumilli2, Marjorie G. Zauderer1

1Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
2Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

*Corresponding author: Michael Offin, MD, Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, MSK Mesothelioma Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Tel: +1 646 608 3763; Fax: +1 646 227 7276; Email: offinm@mskcc.org

Introduction

Mesotheliomas are a heterogeneous group of malignancies involving serosal surfaces comprised of distinct histologic subtypes, including epithelioid, biphasic (mixed), and sarcomatoid. Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma and the type most often studied in prospective clinical trials. Despite advances in our understanding of the molecular landscape of MPM, there is still a paucity of prospectively validated biomarkers of response and resistance hindering our ability to tailor treatment regimens to a patient's cancer. Even with more than 2 dozen phase III trials, there have been few changes in patient outcomes and practice patterns with only 2 FDA approved treatment regimens, both of which are in the first-line setting: combination cisplatin/pemetrexed5 and combination nivolumab/ipilimumab.6 In this commentary, we will discuss the trials that have shaped the first-line treatment landscape for patients with advanced/unresectable MPM and provide perspective on the real-world integration of first-line immune checkpoint inhibitors (ICIs) into clinical practice.

Cytotoxic Chemotherapy

Until recently, systemic cytotoxic chemotherapy was the de facto standard-of-care initial treatment option for patients with unresectable MPM. The EMPHACIS trial, evaluating cisplatin and pemetrexed vs cisplatin alone, noted a clinically meaningful improvement in outcomes with the combination (median overall survival [OS]: 12.1 vs 9.3 months, respectively), and ultimately led to FDA-approval of the combination.5 Although cisplatin is preferable, many patients with MPM are not cisplatin candidates due to intercurrent medical comorbidities; studies have shown that carboplatin may be substituted for cisplatin in these patients.7 Of note, neither of the above-mentioned regimens integrated cytotoxic maintenance chemotherapy.

Integration of Anti-angiogenic Inhibition

The role of maintenance therapy after the completion of a platinum doublet has been the topic of extensive investigation, including in several negative trials to date.9-11 The phase III MAPS trial, which added the vascular endothelial growth factor inhibitor (VEGFi), bevacizumab, to cisplatin and pemetrexed also included maintenance bevacizumab and found an OS (18.8 vs 16.1 months) and progression-free survival (PFS; 9.2 vs 7.3 months) benefit compared to platinum doublet alone.12 However, this trial did not compare efficacy of treatment with or without the bevacizumab maintenance. The recently published phase II NVALT19 trial noted switch-maintenance gemcitabine after the completion of a platinum backbone significantly improved PFS compared with surveillance alone (6.2 vs 3.2 months, respectively), but data on OS have yet to be reported and further investigation in a randomized setting is warranted.13 The phase II/III DENIM trial evaluating the role of allogeneic mesothelioma tumor lysate-loaded dendritic cell therapy (MesoPher) after completion of first-line chemotherapy is ongoing and results to date are unknown.14

The Oncologist, 2022, 27, 610–614
https://doi.org/10.1093/oncolo/oyac113
Advance access publication 16 June 2022

Commentary
and fibroblast growth factor receptor [FGFR]) in combination with cisplatin and pemetrexed failed to show a PFS benefit over chemotherapy alone.\textsuperscript{17} As such, the only currently recognized VEGFi to be considered in the first-line setting is bevacizumab in combination with platinum and pemetrexed. Investigation into the utility of leveraging the immunomodulatory effects of VEGFi with ICI\textsuperscript{18} is ongoing in the first-line setting with the currently accruing phase III BEAT-meso trial (NCT03762018) combining platinum, pemetrexed, and bevacizumab with atezolizumab.

**Targeted Therapies**

With a growing understanding of the molecular landscape of MPM\textsuperscript{1,2,19} there have been several investigations in the first-line setting evaluating potential targeted therapies in MPM. Most are focused on evaluating activity in previously treated patients.\textsuperscript{20-24} Noteworthy completed and ongoing trials in the first-line setting include:

1. **NF2:** The phase II COMMAND trial evaluated the FAK inhibitor, defactinib, as maintenance after completion of platinum and pemetrexed leveraging preclinical work noting moesin-ezrin-radixin-like protein (merlin) deficiency, as seen in NF2 mutant tumors, sensitized to FAK inhibition.\textsuperscript{25} The trial failed to show OS or PFS benefits with the addition of defactinib maintenance compared with placebo, including when stratified by low versus high merlin expression.\textsuperscript{9}

2. **ASS1:** Loss of enzymatic activity of argininosuccinate synthetase 1 (ASS1) is enriched in non-epithelioid subsets of MPM and leads to dependence on exogenous arginine.\textsuperscript{26} In the randomized phase II trial by Szlosarek et al.,\textsuperscript{27} it was noted that treatment with ADI-PEG20, a pegylated arginine deaminase that scours-free arginine, was tolerable and improved PFS compared to best supportive care in the later-line setting. Furthermore, the phase I TRAP trial found that the combination of ADI-PEG20 with cisplatin and pemetrexed in the first-line setting was tolerable.\textsuperscript{24} Based on these findings, the phase II/III ATOMIC-meso trial is under way evaluating ADI-PEG20 combined with a platinum doublet vs platinum doublet alone focusing on the treatment of patients with non-epithelioid MPM (NCT02709512).

3. **Heat shock protein 90:** The phase Ib MESO-02 trial showed safety and potential benefit of the integration of the heat shock protein 90 inhibitor, ganetespib, with platinum/pemtrexed and a potential negative correlation with response and the presence of global loss of heterozygosity.\textsuperscript{29}

Further integration of our growing understanding of potential molecular targets in mesothelioma and interrogation of targeted therapeutics in first-line treatment is needed.

**First-Line ICI**

Immunotherapy has been extensively studied in the later-line setting for patients with MPM.\textsuperscript{30-38} However, it was not until the recent phase III CheckMate 743 trial\textsuperscript{8} that ICI was incorporated into the first-line setting. Checkmate 743 randomized patients with previously untreated and unresectable MPM to platinum and pemetrexed (chemotherapy) vs nivolumab and ipilimumab (dual-ICI).\textsuperscript{6} The dual-ICI cohort had better OS compared with the chemotherapy cohort (18.1 vs 14.1 months, HR = 0.74, 95% CI, 0.60-0.91). Grades 3-4 adverse events were found in approximately 30% of patients in both arms; however, more patients required treatment discontinuation in the dual-ICI arm (15%) compared with the chemotherapy arm (7.4%). These results led to FDA approval of dual-ICI treatment in the first-line setting.\textsuperscript{39}

In a prespecified analysis by histology, which was a stratification factor for randomization, the OS benefit in non-epithelioid MPM was dramatic, 18.1 months for the dual-ICI cohort vs 8.8 months for the chemotherapy cohort (HR = 0.46, 95% CI 0.31-0.68). However, among patients with epithelioid MPM, which comprises approximately two-thirds of MPM tumors, there was no statistically significant survival advantage with dual-ICI vs chemotherapy (18.7 vs 16.5 months, HR = 0.86, 95% CI, 0.69-1.08) and a signal for an initial detriment in PFS with dual-ICI in the first 6 months. Although programmed death-ligand 1 (PD-L1) was not a prespecified stratification factor for randomization, sub-group analysis by PD-L1 expression was prespecified and demonstrated that patients whose tumors had PD-L1 ≥ 1% had improved OS (HR = 0.69; 95% CI, 0.55-0.87) with dual-ICI while PD-L1 negative disease showed no benefit (HR = 0.94; 95% CI, 0.62-1.40).

CheckMate 743 is a practice-changing trial for the treatment of patients with MPM; however, there are several caveats to adopting dual-ICI as first-line treatment for patients with MPM:

1. The benefit for patients with epithelioid MPM is unclear: While there was meaningful improvement in OS for patients with non-epithelioid MPM treated with dual-ICI compared with chemotherapy, this was not the case in the epithelioid subset (which comprised 75% of the study population). For patients with epithelioid MPM, it is unclear what the appropriate sequence of treatments may be, and because of this unanswered question, the NCCN guidelines include a footnote, indicating that dual-ICI is preferred in non-epithelioid histology and an option for patients with epithelioid histology.\textsuperscript{15}

2. The control arm in Checkmate 743 used a regimen inferior to the triplet therapy included in the NCCN guidelines: platinum, pemetrexed, and bevacizumab. Bevacizumab provides an incremental survival advantage over cisplatin and pemetrexed alone.\textsuperscript{12} While the addition of a VEGFi would likely not have substantially altered the benefit among non-epithelioid patients, inclusion of bevacizumab for the epithelioid subset could have altered the results.

3. Since PD-L1 was not a prespecified stratification factor, unlike histology, we do not know if the results associated with PD-L1 expression are just a surrogate for histology. Further prospective analyses including consideration of a multivariate analysis of these findings accounting for epithelioid vs non-epithelioid histology would be useful to demonstrate that the potential signal of benefit observed among patients with PD-L1-positive tumors is not confounded by other prognostic variables.\textsuperscript{40}

4. For the 26% of patients 75 years of age and older in CheckMate 743, there was no benefit of dual-ICI...
compared with chemotherapy (HR = 1.02; 95% CI, 0.70-1.48). Therefore, the generalizability of the overall study results to elderly patients who disproportionately experience MPM may not be appropriate.

(5) Resectability, or lack thereof, in MPM is difficult to define due to the diffuse nature of the disease and varied criteria among institutions. Nearly half of the patients in CheckMate 743 were reported as having stages I-III disease which are considered potentially resectable. Further details on how patients were deemed unresectable would be beneficial as the population most likely to benefit from dual-ICI is defined.

CheckMate 743 noted a striking benefit of dual-ICI in patients with non-epithelioid MPM. This differentiated response based on routinely available pathologic information (epithelioid vs non-epithelioid) represents a much-needed step toward a more refined approach for patient selection for systemic therapy. For patients with non-epithelioid histology, especially those under the age of 75, the use of first-line dual-ICI is preferable over platinum-based chemotherapy. However, in epithelioid MPM and patients 75 years or older, the benefit of first-line dual-ICI compared with chemotherapy has not been established. Further study should focus on refinement of selection criteria that drives toward the biologic underpinnings of response to ICI therapy.

Analogous to the treatment of non-small cell lung cancers (NSCLC), providers must devise a more personalized approach to address the biological and clinical heterogeneity of MPM. For too long, we have implemented treatment modalities using sweeping generalizations to all comers based on resectability; the definition of which, and staging techniques used, at times, is nebulous and not well annotated in prospective trials. Unresectable can mean many things, ranging from technically unresectable due to tumor stage to medically inoperable due to age/comorbidities and thus represents an incomplete description of a complex clinical decision. As we continue to learn more about genomic heterogeneity,12 differential outcomes by histology,16 and the potential roles of biomarkers of response to dual-ICI,42-46 we must integrate these variables into prospective trials to continue refining treatment decisions. While combination treatment with nivolumab and ipilimumab was associated with clinical benefit, we still have only a nascent understanding of biomarkers of response to dual-ICI in MPM. While the CheckMate 743 trial did collect archival tumor samples at enrollment and 2 optional biopsies on treatment, no correlates were reported to date; future analyses of these samples to further refine our understanding of potential predictors of response are eagerly awaited.

Future Directions of Immune Checkpoint Inhibition in the First-Line Setting

With the integration of nivolumab and ipilimumab in the treatment naive setting, we must continue to integrate ICIs into the care paradigm using informed approaches. The phase III CONFIRM trial recently noted OS benefit compared with placebo when patients, particularly those with epithelioid histology, received nivolumab after progression on initial platinum/pemetrexed therapy; emphasizing the need, especially in epithelioid MPM, to further evaluate the proper sequencing of chemotherapy and immunotherapy.47 The DREAM3R trial (NCT04334759) has launched to compare combination chemo-immunotherapy with durvalumab to chemotherapy alone based off the recently published DREAM trial.48 The BEAT-meso trial is currently evaluating the potential incremental benefit of adding VEGF inhibition to a chemo-immunotherapy backbone (NCT03762018). Multiple trials are also examining the safety and efficacy of incorporating ICIs into the perioperative management of MPM (NCT04162015, NCT03918252). Novel immunotherapeutic approaches remain vital to addressing ICI resistance or failure, and many promising constructs, such as mesothelin-directed chimeric antigen receptor T cells (NCT04577326),49,50 trispecific mesothelin-engaging antibodies (NCT03872206), dendritic cell therapy (NCT02649829), genetically modified adenovirus (NCT03710876, NCT04013334), and VISTA cell therapy (NCT04475523) antibodies, are under study.

Conclusion

For the first time in nearly 2 decades, there has been an FDA approval in MPM allowing for the integration of first-line ICI.6,39 As has often been the case in the treatment of patients with mesothelioma, the decision between first-line dual-ICI versus systemic chemotherapy involves the integration of a complex amalgam of several clinical factors, and our understanding of potential predictors of response is still relatively limited. With progress comes new questions and the need to re-evaluate trial design, stratification, and enhance our approaches to biomarker development. Integration of novel treatment paradigms, including combination chemo-immunotherapy, targeted agents, vaccines, and potential cellular therapeutics in the earlier-line setting are needed. Future trials should leverage our growing understanding of the histologic and molecular heterogeneity of mesothelioma and strive to develop companion biomarkers so patients can be matched to the treatments from which they will derive the most benefit.

Funding

This work was partially supported by a National Cancer Institute Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Conflict of Interest

Michael Offin: PharmaMar, Novartis, Targeted Oncology, Bristol-Myers Squibb, Merck Sharp & Dohme, Jazz Pharmaceuticals (Other—personal fees); Valerie W. Rusch: National Institutes of Health/National Cancer Institute, Genelux, Inc., Genentech, (RF), DaVinci Surgery (Other), Bristol Myers Squibb (Other—non-financial support), NIH/Coordinating Center For Clinical Trials (Other—personal fees); Andreas Rimmer: Varian Medical Systems, AstraZeneca, Boehringer Ingelheim, Merck, Pfizer, Research to Practice, Cybexra, More Health (RF), AstraZeneca, Merck, Research to Practice, Cybexra, More Health (Other—personal fees), Philips/Elekta (Other—non-financial support); Prasad S. Adusumilli: National Institutes of Health/National Cancer Institute, Department of Defense, Atara Biotherapeutics (RF), patent US20180251546A1 licensed to Atara Biotherapeutics, patent WO2018165228A1 pending, patent

The Oncologist, 2022, Vol. 27, No. 8
CA3034691A1 pending, patent US20170172477A1 pending, a patent CA3007980A1 pending, patent AU2016316033A1 pending, patent EP1979900B1 issued (IP); Marjorie G. Zauderer: Atara, National Institutes of Health/National Cancer Institute, Department of Defense, Epizyme, Sellas Life Sciences, MedImmune, Polaris, Bristol Myers Squibb, Curis, Millennium/Takeda, GlaxoSmithKline (RF), Roche (Other—non-financial support), Aldeyra Therapeutics, Atara, GlaxoSmithKline, Millennium/Takeda, Novocure (Other—personal fees), Mesothelioma Applied Research Foundation, IBM (Other).

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent

Author Contributions

Conception/design: All authors. Manuscript writing: All authors. Final approval of manuscript: All authors.

References

1. Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2019;9(12):1548-1565. https://doi.org/10.1158/2159-8290.CD-18-0804.
2. Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407-416. https://doi.org/10.1038/ng.3520.
3. Zauderer MG, Martin A, Egger J, et al. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. Lancet Digit Health 2021;3(9):e565-e576. https://doi.org/10.1016/S2589-7500(21)00104-7.
4. Courtiol P, Maussion C, Moarri M, et al. Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat Med. 2019;25(10):1519-1525. https://doi.org/10.1038/s41591-019-0583-3.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. https://doi.org/10.1200/JCO.2003.11.136.
6. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. https://doi.org/10.1016/S0140-6736(20)31274-8.
7. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2000;18(9):1443-1448. https://doi.org/10.1200/JCO.2000.04.3190.
8. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370-373. https://doi.org/10.1093/annonc/mdm301.
9. Fennell DA, Baas P, Taylor P, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratiﬁed pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study. J Clin Oncol. 2019;37(10):790-798. https://doi.org/10.1200/JCO.2018.79.0543.
10. Dudek AZ, Wang XE, Gu L, et al. Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). J Clin Oncol. 2019;37(15_suppl):8517-8517.
11. Buikhuizen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013;14(6):543-551. https://doi.org/10.1016/S1470-2045(13)70125-6.
12. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405-1414. https://doi.org/10.1016/S0140-6736(15)01238-6.
13. de Gooijer CJ, van der Noort V, Stigt JA, et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med. 2021;9(6):585-592. https://doi.org/10.1016/S2213-2600(20)30662-3.
14. Belderbos RA, Baas P, Berardi R, et al. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DEnDritic cell Immunotherapy for Mesothelioma (DENIM) trial. Trans Lung Cancer Res. 2019;8(3):280-285. https://doi.org/10.21037/ tlcr.2019.05.05.
15. NCN. Malignant Pleural Mesothelioma (Version 1.2021). 2021. Available at https://www.ncn.org/professionals/physician_gls/pdf/mpm.pdf.
16. Tsao AS, Miao J, Wistuba II, et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naïve patients with unresectable malignant pleural mesothelioma (SWOG S0905). J Clin Oncol. 2019;37(28):2537-2547.
17. Scaglioni GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019;7(7):569-580. https://doi.org/10.1016/S2213-2600(19)30139-0.
18. Fukumura D, Kloopper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325-340. https://doi.org/10.1038/nrclinonc.2018.29.
19. Bort M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-672. https://doi.org/10.1038/ng.855.
20. Fennell DA, King A, Mohammed S, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593-600. https://doi.org/10.1016/S2213-2600(20)30390-8.
21. Zauderer MG, Szlosarek P, Moulec SL, et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation. J Clin Oncol. 2018;36(15_suppl):8515-8515.
22. Fennell D, Hudka M, Darlison L, et al. P2.06-02 mesothelioma stratified therapy (MiST): a phase II AIA umbrella trial for accelerating the development of precision medicines. J Thorac Oncol. 2019;14(10_suppl):S753-S756.
23. Hassan R, Mian I, Wagner G, et al. Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germ-line and somatic mutations in DNA repair genes. J Clin Oncol. 2020;38(15_suppl):9054-9054.
24. Fennell DA, King A, Mohammed S, et al. A Phase II trial of abemac- iclib in patients with p16ink4a negative, relapsed mesothelioma. J Clin Oncol. 2021;39(15_suppl):8558-8558.
25. Shapiro IM, Kolev VN, Vidal CM, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra268-237ra268.

26. Szlosarek PW, Klabsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res. 2006;12(23):7126-7131. https://doi.org/10.1158/1078-0432.CCR-06-1101

27. Szlosarek PW, Steele JP, Nolan L, et al. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol. 2017;3(1):58-66. https://doi.org/10.1001/jamaoncol.2016.3049

28. Beddowes E, Spicer J, Chan PY, et al. Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers. J Clin Oncol. 2017;35(16):1778-1785. https://doi.org/10.1200/JCO.2016.71.3230

29. Fennell DA, Danson S, Woll PJ, et al. Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural mesothelioma (Meso-02): a phase Ib trial. Clin Cancer Res. 2020;26(18):4748-4755. https://doi.org/10.1158/1078-0432.CCR-20-1306

30. Kindler H, Karrison T, Carol Tan Y-H, et al. OA13.02 Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis. J Thorac Oncol. 2017;12(1):S293-S294.

31. Desai A, Karrison T, Rose J, et al. Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol. 2018;36(15_suppl):8565-8565.

32. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol 2018;13(10):1569-1576. https://doi.org/10.1016/j.jtho.2018.05.038

33. Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol 2019;5(3):351-357. https://doi.org/10.1001/jamaoncol.2018.5428

34. Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261-1273. https://doi.org/10.1016/S1470-2045(17)30446-1

35. Scherpereel A, Mazieres J, Grellier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239-253. https://doi.org/10.1016/S1470-2045(18)30765-4

36. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260-270. https://doi.org/10.1016/S2213-2600(18)30420-X

37. Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451-460. https://doi.org/10.1016/S2213-2600(18)30151-6

38. Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485-5492. https://doi.org/10.1158/1078-0432.CCR-19-0103

39. Nakajima EC, Vellanki PJ, Larkins E, et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446-451. https://doi.org/10.1158/1078-0432.CCR-21-1466

40. Thapa B, Salcedo A, Lin X, et al. The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J Thorac Oncol. 2017;12(5):850-859. https://doi.org/10.1016/j.jtho.2017.02.013

41. Pass HI, Giroux D, Kennedy C, et al. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014;9(6):856-864. https://doi.org/10.1097/JTO.0000000000000181

42. Mankor JM, Disselhorst MJ, Poncin M, et al. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine. 2020;62:103040. https://doi.org/10.1016/j.ebiomed.2020.103040

43. Vroman H, Balzaretti G, Belderbos RA, et al. T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. J Immunother Cancer. 2020;8(1):e000251. https://doi.org/10.1136/jitc-2019-000251

44. Ladanyi M, Sanchez Vega F, Zauderer M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Med. 2019;11(1):18. https://doi.org/10.1186/s13073-019-0631-0

45. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms’ tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13(15 Pt 1):4547-4555. https://doi.org/10.1158/1078-0432.CCR-07-0708

46. Uijie H, Kadota K, Nitadori JJ, et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4(6):e1009285. https://doi.org/10.1080/2162402X.2015.1009285

47. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530-1540. https://doi.org/10.1016/S1470-2045(21)00471-X

48. Nowak AK, Lesterhuis WJ, Kok P-S, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213-1223. https://doi.org/10.1016/S1470-2045(20)30462-9

49. Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra-26151.

50. Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-3144. https://doi.org/10.1172/JCI83092